Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue GuidanceGlobeNewsWire • 08/02/23
August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 07/31/23
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in ChinaGlobeNewsWire • 07/13/23
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)GlobeNewsWire • 05/17/23
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/03/23
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week ConferenceGlobeNewsWire • 05/01/23
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023GlobeNewsWire • 04/26/23